90 results about "ALK inhibitor" patented technology

This invention relates to novel ALK inhibitors of Formula I:

as defined in the specification, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering ALK inhibitors.

The invention provides a pyrimidine derivative used as an ALK inhibitor. The pyrimidine derivative is a compound as shown in a formula I which is described in the specification or a pharmaceutical salt, hydrate, solvate, metabolite or prodrug thereof. R1, R2, R3 and R4 in the formula are as defined in the specification. The compound and a pharmaceutical composition thereof can be used as the ALK inhibitor and for preparation of an antineoplastic therapeutic capable of inhibiting ALK.

The invention provides a kinase inhibitor and application thereof. The compound is a compound shown in a formula I or pharmaceutical salt, a hydrate, a solvate, a metabolite or a prodrug of the compound shown in the formula I, wherein R1 and R2 are defined in the description. The compound and a pharmaceutical composition can be used for preparing an ALK inhibitor and drugs for treating or preventing cancers and inhibiting the proliferative effect of cancer cells. The formula I is shown in the description.

The invention relates to the fields of cytobiology and cell culture, and particularly relates to a breast cancer organoid culture kit. A method for realizing the kit comprises the following steps: (1)preparing, sub-packaging and using a breast cancer organoid culture medium A; (2) preparing, sub-packaging and using a breast cancer organoid culture medium B; and (3) preparing, sub-packaging and using a sample preserving fluid. The breast cancer organoid culture medium A is a DMEM/F12 culture medium containing 100 U/ml of penicillin, 0.1 mg/ml of streptomycin, 1% of HEPES and 1% of Gluta Max 100 X; the organoid culture medium B is a DMEM/F12 culture medium containing EGF, an FGF growth factor, an ALK inhibitor A83-01, Noggin, an HEPES buffer solution, Y27632 and one or more of a Wnt signalpath related secretory protein family R-Spondin 1-4; and the sample preserving fluid is a DMEM/F12 culture medium containing 100 U/ml of penicillin, 0.1 mg/ml of streptomycin and 1% of L-glutamine. The three components form the breast cancer organoid culture kit.

The invention discloses a preparation method of an ALK inhibitor crizotinib and analogue or salt thereof. The method comprise the following steps: 1, 1-(4'-N-Boc)-1'-piperidine-3(3''-fluoro-2''-nitro)-5''-pyridylpyrazole is prepared; 2, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-N-Boc-piperidinyl)-1H-pyrazol-4-yl]-2-nitropyridine is prepared; 3, N-Boc crizotinib is prepared; and 4, crizotinib and analogue or salt thereof is prepared. The method has the following advantages: the synthesis steps are reduced to 4 chemical reaction steps; a total yield is improved to approximately 35%, while the yield of an existing method is only approximately 10%; phenethyl alcohol with (R)- configuration, such as (R)-2,6-dichloro-3-fluorophenylethanol, is directly used as a raw material, such that the raw material can be fully utilized. The method provided by the invention is suitable for industrialized productions.

The invention discloses application of a pyridylamine compound in preparation of a pharmaceutical composition used for treating a lung cancer and suitable for oral administration and aims to overcome problems in effective application of an ALK inhibitor in treatment. The pharmaceutical composition provided by the invention contains the pyridylamine compound having a structure as represented by formula I, an active component and an optional pharmaceutically acceptable carrier, adjuvant or excipient, wherein the active component is one or a mixture of two selected from the group consisting of pharmaceutically acceptable salts of the pyridylamine compound, and the effective treatment dose of the pharmaceutical composition is 340 to 680 mg/d in terms of the amount of the pyridylamine compound having the structure as represented by formula I. The pyridylamine compound can be effectively applied in treatment of EML4-ALK-positive non-small cell lung cancers and has a substantial treatment effect and low toxic response.

The invention relates to a compound as shown in a formula (I) which is described in the specification, and a pharmaceutical composition and a preparation method thereof. The compound can be used as anALK inhibitor for treatment of diseases mediated by ALK. The invention further relates to application of the compound as shown in the formula (I) and the pharmaceutical composition thereof to preparation of drugs used for treating diseases mediated by ALK.

The invention discloses a neural stem cell induction differentiation medium and a neural stem cell induction differentiation method. Specifically, the neural stem cell induction differentiation mediumcomprises a basic medium and additives. The basic medium is a DMEM/F12 medium. The additives include 1-5mM glutamine, a 2-8microM GSK-3 inhibitor, a 2-10microM BMP inhibitor, a 2-10microM ALK inhibitor, 0.5%-2% of a cell culture additive and 0.5%-2% of a double-antibody. The neural stem cell induction differentiation medium provided by the invention has the characteristics of clear and simple components, high differentiation efficiency, short differentiation time, no animal-derived component, no need for animal-derived cells to serve as the feeder layer during differentiation, no need to formEB, and no need for repeated replacement of the culture solution components in differentiation, and can acquire a large number of high purity neural stem cells within a short time.

The invention discloses a culture medium for culturing neural stem cells on the basis of peripheral blood mononuclear cells. The culture medium comprises components as follows: a DMEM/F12 culture medium and a neurobasal medium in a volume ratio being 1:0.8-1.2 as well as an adenylate cyclase activator, a serum substitute, L-ascorbic acid, an L-glutamine derivative, an ALK inhibitor, a GSK-3 inhibitor, an ALK-2,3,6,AMPK inhibitor and an ALK-4,5,7 inhibitor. The invention further discloses a method for culturing the neural stem cells on the basis of the peripheral blood mononuclear cells. With adoption of the culture medium, the neural stem cells can be obtained from the peripheral blood mononuclear cells as the raw material through directional differentiation culture, materials are taken conveniently and free of quantitative restriction, and moral controversy can be avoided.

A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

The present invention relates to a compound represented by a formula (I), a pharmaceutical composition and a preparation method thereof, wherein the compound can be used as an ALK inhibitor to treat ALK-mediated diseases. The invention further relates to the preparation method of the compound represented by the formula (I), and applications of the compound represented by the formula (I) and the pharmaceutical composition thereof in preparation f drugs for treatment of ALK-mediated diseases. The formula (I) is defined in the specification.

The invention discloses a spiro aryl sulfone compound, and especially relates to the compound represented by the formula (I) as an ALK inhibitor.

A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining Anaplastic Lymphoma Kinase Inhibitors (ALK Inhibitors) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises ALK Inhibitors administered according to a continuous regimen based on an average daily dose in the range of 10 to 250 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.